New study probes exercise breathing in CF patients on breakthrough drug

NCT ID NCT07314229

Recruiting now Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how cystic fibrosis patients who take the drug combination Elexacaftor-Tezacaftor-Ivacaftor (ETI) breathe during exercise. Researchers will measure lung function while patients walk or step, aiming to find out how many have limited breathing capacity. The results may help tailor exercise advice for these patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better understand how well cystic fibrosis patients on ETI therapy can exercise, potentially guiding personalized rehabilitation programs.
What could go wrong: This is an observational study, not testing a new treatment. It only measures breathing during exercise, so it won't directly improve health or change therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS (CF) MUCOVISCIDOSIS

Contacts and locations

Locations

University Hospital
RECRUITING

Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.